Beyond antibiotics: New therapeutic approaches for bacterial infections

Clinical Infectious Diseases

Volumn 63, Issue 1, 2016, Pages 89-95

  Hauser, Alan R ^a   Mecsas, Joan ^b   Moir, Donald T ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MICROBIOTIX INC   (United States)

Author keywords

Antivirulence therapy; Bacteria; Microbiome.; Phage therapy; Secretion systems

Indexed keywords

ANTHRAX TOXIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL SECRETION SYSTEM; VIRULENCE FACTOR;

ANTIBIOTIC THERAPY; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL INFECTION; BACTERIAL SECRETION SYSTEM; BACTERIAL VIRULENCE; BACTERIOPHAGE; BACTERIUM ADHERENCE; BIOFILM; HUMAN; INFECTION PREVENTION; LACTOBACILLUS; MICROBIOME; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUORUM SENSING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SACCHAROMYCES BOULARDII; STREPTOCOCCUS SALIVARIUS; SURVIVAL RATE; ANIMAL; BACTERIAL INFECTIONS; MEDICAL RESEARCH; MICROBIOLOGY; MICROFLORA; MOUSE; PHAGE THERAPY; PROCEDURES;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIAL SECRETION SYSTEMS; BACTERIOPHAGES; BIOMEDICAL RESEARCH; HUMANS; MICE; MICROBIOTA; PHAGE THERAPY; VIRULENCE FACTORS;

EID: 84981276005     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw200     Document Type: Article

References (19)

1. Jorgensen JH, Ferraro MJ. Antimicrobial susceptibility testing: A review of general principles and contemporary practices. Clin Infect Dis 2009 49:1749-55.
2. Food and Drug Administration Center for Devices and Radiological Health. Guidance for Industry and FDA: class II special controls guidance document: Antimicrobial susceptibility test (AST) systems. Rockville, MD: US Department of Health and Human Services, 2009.
3. Food and Drug Administration Center for Devices and Radiological Health. Review criteria for assessment of antimicrobial susceptibility test discs. Rockville, MD: US Department of Health and Human Services, 1996.
4. US Food and Drug Administration. Antibacterial and antifungal product labeling: microbiology susceptibility interpretive criteria (breakpoints) and quality control parameter updates. Available at: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm275763.htm. Accessed 8 April 2016.
5. Clinical and Laboratory Standards Institute. Development of in vitro susceptibility testing criteria and quality control parameters. 4th ed. CLSI guideline M23. Wayne, PA: CLSI, 2016.
6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI guideline M100S. 26th ed.Wayne, PA: CLSI, 2016.
7. Turnidge JD. Cefazolin and Enterobacteriaceae: Rationale for revised susceptibility testing breakpoints. Clin Infect Dis 2011; 52:917-24.
8. Kahlmeter G. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae- EUCAST and CLSI breakpoints. Clin Microbiol Infect 2008; 14:169-74.
9. Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN. Background and rationale for revised clinical and laboratory standards institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and aztreonam. Clin Infect Dis 2013; 56:1301-9.
10. Thaden JT, Lewis SS, Hazen KC, et al. Rising rates of carbapenem-resistant Enterobacteriaceae in community hospitals: A mixed-methods review of epidemiology and microbiology practices in a network of community hospitals in the southeastern United States. Infect Control Hosp Epidemiol 2014; 35:978-83.
11. Jenkins S, Jerris R. Critical assessment of issues applicable to development of antimicrobial susceptibility testing breakpoints. J Clin Microbiol 2011; 49:S5-S10.
12. Bulik CC, Fauntleroy KA, Jenkins SG, et al. Comparison of meropnem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods. J Clin Microbiol 2010; 48:2402-6.
13. Bobenchik AM, Deak E, Hindler JA, Charlton CL, Humphries RM. Performance of Vitek 2 for antimicrobial susceptibility testing of Enterobacteriaceae with Vitek 2 (2009 FDA) and 2014 CLSI breakpoints. J Clin Microbiol 2015; 53:816-23.
14. Jones RN, Farrell DJ, Flamm RK, Sader HS, Dunne MW, Mendes RE. Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. Diag Microbiol Infect Dis 2015; 82:73-7.
15. Jones RN, Turnidge JD, Moeck G, Arhin FF, Mendes RE. Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long- Acting lipoglycopeptide. Antimicrob Agents Chemother 2015; 59:2405-9.
16. Mendes RE, Farrell DJ, Flamm RK, Sader HS, Jones RN. Analysis of vancomycin susceptibility testing results for presumptive categorization of telavancin. J Clin Microbiol 2015; 53:2727-30.
17. Zurenko G, Bien P, Bensaci M, Patel HN, Thorne G. Use of linezolid susceptibility test results as a surrogate for the susceptibility of gram-positive pathogens to tedizolid, a novel oxazolidinone. Ann Clin Microbiol Antimicrob 2014; 13:46.
18. Sader HS, Farrell DJ, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against aerobic gram-negative organisms isolated from intra- Abdominal and urinary tract infections in European and United States hospitals (2012). J Infect 2014; 69:266-77.
19. Humphries RM, Yang S, Hemarajata P, et al. First report of ceftazidime- Avibactam resistance in a KPC-3 expressing Klebsiella pneumoniae. Antimicrob Agents Chemother 2015; 59:6605-7.